Haemophilus Influenzae Type b Clinical Trial
Official title:
Assessment of Long-term Antibody Persistence After a Booster Dose of GSK Biologicals' Hib & Meningococcal C Vaccine (Menitorix™) 811936 Given at 12-15 Months of Age to Subjects Primed With 3 Doses of Menitorix™ at 2, 3, 4 Months of Age
Verified date | June 2020 |
Source | GlaxoSmithKline |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the long-term antibody persistence at 12, 24 and 48
months after the administration of a booster dose of Menitorix™, given at 12-15 months of
age. The children had previously received 3 doses of Menitorix™ and Infanrix IPV™ or
Meningitec™ and Pediacel™ in infancy. In addition, the antibody persistence is to be
investigated in children of 40-43 months of age who received a 3-dose primary vaccination of
a MenC conjugate vaccine and a Hib containing vaccine in infancy without a booster dose of
MenC conjugate and Hib vaccine in the second year of life.
This protocol posting deals with objectives & outcome measures of the extension phases at 12,
24 and 48 months after the booster phase. The links to objectives and outcome measures of the
primary phase & booster phase at 12 to 15 months are provided below:
https://www.gsk-studyregister.com/study/2747 (Primary phase)
https://www.gsk-studyregister.com/study/2755 (Booster phase)
Status | Completed |
Enrollment | 288 |
Est. completion date | October 12, 2007 |
Est. primary completion date | October 12, 2007 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 24 Months to 64 Months |
Eligibility |
Inclusion Criteria: Subjects of groups HibMenC and LicMenC at Visits 1, 2 and 3: - Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol. - A male or female between and including 24 and 31 months of age at the time of Visit 1, between and including 40 and 43 months of age at Visit 2 and between and including 60 and 64 months at Visit 3. - Written informed consent obtained from the parent or guardian of the subject. - Healthy subjects as established by medical history and clinical examination before entering into the study. - Having completed the booster vaccination study 104056. Subjects of group NoBoost at Visit 2 (UK only): - Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol. - A male or female between and including 40 and 43 months of age at Visit 2. - Written informed consent obtained from the parent or guardian of the subject. - Healthy subjects as established by medical history and clinical examination before entering into the study. - Having received a 3-dose primary vaccination with a MenC conjugate vaccine and a Hib containing vaccine before the age of 8 months. Exclusion Criteria: - Previous administration of booster dose of Hib or meningococcal serogroup C except booster study vaccines during the study 104056. - History of H. influenzae type b or meningococcal diseases. - For UK subjects of groups HibMenC and LicMenC only: previous administration of a booster dose of a pertussis-containing vaccine except booster study vaccines during the study 104056. |
Country | Name | City | State |
---|---|---|---|
Poland | GSK Investigational Site | Bydgoszcz | |
Poland | GSK Investigational Site | Gdansk | |
Poland | GSK Investigational Site | Kielce | |
Poland | GSK Investigational Site | Krakow | |
Poland | GSK Investigational Site | Leczna | |
Poland | GSK Investigational Site | Poznan | |
Poland | GSK Investigational Site | Siemianowice Slaskie | |
Poland | GSK Investigational Site | Trzebnica | |
United Kingdom | GSK Investigational Site | Oxford | Oxfordshire |
Lead Sponsor | Collaborator |
---|---|
GlaxoSmithKline |
Poland, United Kingdom,
Khatami A et al. Antibody concentrations against pertussis antigens at age 5 years following infant and pre-school immunisation: follow-on of a randomized controlled trial. Abstract presented at the 7th World Congress for World Society for Pediatric Infectious Diseases (WSPID). Melbourne, Australia, 16-19 November 2011.
Khatami A et al. Persistence of antibody response following a booster dose of Hib-MenC-TT glycoconjugate vaccine: A phase IV open randomized controlled trial. Abstract presented at the 27th annual ESPID meeting, Brussels, Belgium, 9-13 June 2009.
Khatami A, Snape MD, John T, Westcar S, Klinger C, Rollinson L, Boutriau D, Mesaros N, Wysocki J, Galaj A, Yu LM, Pollard AJ. Persistence of immunity following a booster dose of Haemophilus influenzae type B-Meningococcal serogroup C glycoconjugate vaccine: follow-up of a randomized controlled trial. Pediatr Infect Dis J. 2011 Mar;30(3):197-202. doi: 10.1097/INF.0b013e3181f728fd. — View Citation
Khatami A, Snape MD, Wysocki J, John TM, Westcar S, Mesaros N, Peddiraju K, Boutriau D, Yu LM, Pollard AJ. Persistence of antibody response following a booster dose of Hib-MenC-TT glycoconjugate vaccine to five years: a follow-up study. Pediatr Infect Dis J. 2012 Oct;31(10):1069-73. doi: 10.1097/INF.0b013e318262528c. — View Citation
Snape MD et al. Persistence of antibody response following a booster dose of Hib-MenC-TT glycoconjugate vaccine to five years: a follow-on study. Abstract presented at the 7th World Congress for World Society for Pediatric Infectious Diseases (WSPID). Melbourne, Australia, 16-19 November 2011.
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Subjects With Serum Bactericidal Assay Using Baby Rabbit Complement (rSBA-MenC) Antibody Titers Equal to or Above 1:8 | The anti-meningococcal serogroup C activity was determined using a serum bactericidal test. The cut-off of the assay is a dilution of 1:8, resulting in 50% inhibition. | At Year 1 | |
Primary | Number of Subjects With rSBA-MenC Antibody Titers = 1:128 | The anti-meningococcal serogroup C activity was determined using a serum bactericidal test. The cut-off of the assay is a dilution of 1:128, resulting in 50% inhibition. | At Year 1 | |
Primary | rSBA-MenC Antibody Titers | Antibody concentrations for the serogroup C serum bactericidal assay using baby rabbit complement were expressed as geometric mean titers (GMT) with 95% confidence intervals (CI). Titers bellow the cut-off of the test were given an arbitrary value of half the cut-off for the purpose of GMT calculation. | At Year 1 | |
Primary | Number of Subjects With rSBA-MenC Antibody Titers =1:8 | The anti-meningococcal serogroup C activity was determined using a serum bactericidal test. The cut-off of the assay is a dilution of 1:8, resulting in 50% inhibition. | At Year 2 | |
Primary | Number of Subjects With rSBA-MenC Antibody Titers = 1:8 for Meningitec+Hiberix Group | The anti-meningococcal serogroup C activity was determined using a serum bactericidal test. The cut-off of the assay is a dilution of 1:8, resulting in 50% inhibition. | At Year 2 | |
Primary | Number of Subjects With rSBA-MenC Antibody Titers = 1:128 | The anti-meningococcal serogroup C activity was determined using a serum bactericidal test. The cut-off of the assay is a dilution of 1:128, resulting in 50% inhibition. | At Year 2 | |
Primary | Number of Subjects With rSBA-MenC Antibody Titers = 1:128 for Meningitec+Hiberix Group | The anti-meningococcal serogroup C activity was determined using a serum bactericidal test. The cut-off of the assay is a dilution of 1:128, resulting in 50% inhibition. | At Year 2 | |
Primary | rSBA-MenC Antibody Titers | Antibody concentrations for anti-serogroup C serum bactericidal assay using baby rabbit complement were expressed as geometric mean titers (GMT) with 95% confidence intervals (CI). Titers below the cut-off of the test were given an arbitrary value of half the cut-off for the purpose of GMT calculation. | At Year 2 | |
Primary | rSBA-MenC Antibody Titers for Meningitec+Hiberix Group | Antibody concentrations for anti-serogroup C serum bactericidal assay using baby rabbit complement were expressed as geometric mean titers (GMT) with 95% confidence intervals (CI). Titers bellow the cut-off of the test were given an arbitrary value of half the cut-off for the purpose of GMT calculation. | At Year 2 | |
Primary | Number of Subjects With rSBA-MenC Antibody Titers = 1:8 | The anti-meningococcal serogroup C activity was determined using a serum bactericidal test. The cut-off of the assay is a dilution of 1:8, resulting in 50% inhibition. | At Year 4 | |
Primary | Number of Subjects With rSBA-MenC Antibody Titers = 1:128 | The anti-meningococcal serogroup C activity was determined using a serum bactericidal test. The cut-off of the assay is a dilution of 1:128, resulting in 50% inhibition. | At Year 4 | |
Primary | rSBA-MenC Antibody Titers | Antibody concentrations for anti-serogroup C serum bactericidal assay using baby rabbit complement were expressed as geometric mean titers (GMT) with 95% confidence intervals (CI). Titers bellow the cut-off of the test were given an arbitrary value of half the cut-off for the purpose of GMT calculation. | At Year 4 | |
Primary | Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibodies Equal to or Above 0.15 Micrograms Per Milliliter (µg/mL) and Equal to or Above 1 Micrograms Per Milliliter (µg/mL) | The anti-polyribosylribitol phosphate was determined using an Enzyme-linked Immunosorbent Assay (ELISA). | At Year 1 | |
Primary | Concentration of Anti-PRP Antibodies | Antibody concentrations for anti-polyribosylribitol phosphate were expressed as geometric mean concentrations (GMC) with 95% confidence intervals (CI), given in µg/mL. Concentrations bellow the cut-off of the test were given an arbitrary value of half the cut-off for the purpose of GMC calculation. | At Year 1 | |
Primary | Number of Subjects With Anti-PRP Antibodies = 0.15 µg/mL and = 1 µg/mL | The anti-polyribosylribitol phosphate was determined using an Enzyme-linked Immunosorbent Assay (ELISA). | At Year 2 | |
Primary | Number of Subjects With Anti-PRP Antibodies =0.15 µg/mL and =1 µg/mL for Meningitec+Hiberix Group | The anti-polyribosylribitol phosphate was determined using an Enzyme-linked Immunosorbent Assay (ELISA). | At Year 2 | |
Primary | Concentration of Anti-PRP Antibodies | Antibody concentrations for anti-polyribosylribitol phosphate were expressed as geometric mean concentrations (GMC) with 95% confidence intervals (CI), given in µg/mL. Concentrations below the cut-off of the test were given an arbitrary value of half the cut-off for the purpose of GMC calculation. | At Year 2 | |
Primary | Concentration of Anti-PRP Antibodies for Meningitec+Hiberix Group | Antibody concentrations for anti-polyribosylribitol phosphate were expressed as geometric mean concentrations (GMC) with 95% confidence intervals (CI), given in µg/mL. Concentrations below the cut-off of the test were given an arbitrary value of half the cut-off for the purpose of GMC calculation. | At Year 2 | |
Primary | Number of Subjects With Anti-PRP Antibodies = 0.15 µg/mL and = 1 µg/mL | The anti-polyribosylribitol phosphate was determined using an Enzyme-linked Immunosorbent Assay (ELISA). | At Year 4 | |
Primary | Concentration of Anti-PRP Antibodies | Antibody concentrations for anti-polyribosylribitol phosphate were expressed as geometric mean concentrations (GMC) with 95% confidence intervals (CI), given in µg/mL. Concentrations below the cut-off of the test were given an arbitrary value of half the cut-off for the purpose of GMC calculation. | At Year 4 | |
Primary | Number of Subjects With Anti-serogroup C Polysaccharide (Anti-PSC) Antibody Concentrations Equal to or Above 0.3 Micrograms Per Milliliter(µg/mL) and Equal to or Above 2 Micrograms Per Milliliter (µg/mL) | The anti-polysaccharide C activity was determined using an Enzyme-linked Immunosorbent Assay (ELISA). | At Year 1 | |
Primary | Concentration of Anti-PSC Antibodies | Antibody concentrations for anti-polysaccharide C were expressed as geometric mean concentrations (GMC) with 95% confidence intervals (CI), given in µg/mL. Concentrations bellow the cut-off of the test were given an arbitrary value of half the cut-off for the purpose of GMC calculation. | At Year 1 | |
Primary | Number of Subjects With Anti-PSC Antibody Concentrations = 0.3 µg/mL and = 2 µg/mL | The anti-polysaccharide C activity was determined using an Enzyme-linked Immunosorbent Assay (ELISA). | At Year 2 | |
Primary | Number of Subjects With Anti-PSC Antibody Concentrations = 0.3 µg/mL and = 2 µg/mL for Meningitec+Hiberix Group | The anti-polysaccharide C activity was determined using an Enzyme-linked Immunosorbent Assay (ELISA). | At Year 2 | |
Primary | Concentration of Anti-PSC Antibodies | Antibody concentrations for anti-polysaccharide C were expressed as geometric mean concentrations (GMC) with 95% confidence intervals (CI), given in µg/mL. Concentrations bellow the cut-off of the test were given an arbitrary value of half the cut-off for the purpose of GMC calculation. | At Year 2 | |
Primary | Concentration of Anti-PSC Antibodies for Meningitec+Hiberix Group | Antibody concentrations for anti-polysaccharide C were expressed as geometric mean concentrations (GMC) with 95% confidence intervals (CI), given in µg/mL. Concentrations bellow the cut-off of the test were given an arbitrary value of half the cut-off for the purpose of GMC calculation. | At Year 2 | |
Primary | Number of Subjects With Anti-PSC Antibody Concentrations = 0.3 µg/mL and = 2 µg/mL | The anti-polysaccharide C activity was determined using an Enzyme-linked Immunosorbent Assay (ELISA). | At Year 4 | |
Primary | Concentration of Anti-PSC Antibodies | Antibody concentrations for anti-polysaccharide C were expressed as geometric mean concentrations (GMC) with 95% confidence intervals (CI), given in µg/mL. Concentrations bellow the cut-off of the test were given an arbitrary value of half the cut-off for the purpose of GMC calculation. | At Year 4 | |
Primary | Number of Subjects With Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations Equal to or Above 5.0 ELISA Units Per Milliliter (EL.U/mL) | The anti-pertussis toxoid, anti-filamentous haemagglutin, anti-pertactin activity was determined using an Enzyme-linked Immunosorbent Assay (ELISA). | At Year 2 | |
Primary | Concentration of Anti-PT, Anti-FHA and Anti-PRN Antibodies | Antibody concentrations for anti-pertussis toxoid, anti-filamentous haemagglutin and anti-pertactin C were expressed as geometric mean concentrations (GMC) with 95% confidence intervals (CI), given in EL.U/mL. | At Year 2 | |
Primary | Number of Subjects With Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations = 5.0 EL.U/mL | The anti-pertussis toxoid, anti-filamentous haemagglutin, anti-pertactin activity was determined using an Enzyme-linked Immunosorbent Assay (ELISA). | At Year 4 | |
Primary | Concentration of Anti-PT, Anti-FHA and Anti-PRN Antibodies | Antibody concentrations for anti-pertussis toxoid, anti-filamentous haemagglutin and anti-pertactin were expressed as geometric mean concentrations (GMC) with 95% confidence intervals (CI), given in EL.U/mL. | At Year 4 | |
Primary | Number of Subjects With Serious Adverse Events (SAEs) | A SAE was defined as any medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity in a subject. AE(s) considered as SAE(s) also included invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that did not result in hospitalization, as per the medical or scientific judgement of the physician. Any = Occurrence of a SAE, regardless of relationship to vaccination. | Up to Month 12 (Booster vaccination) | |
Primary | Number of Subjects With SAE(s) | A SAE was defined as any medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity in a subject. AE(s) considered as SAE(s) also included invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that did not result in hospitalization, as per the medical or scientific judgement of the physician. Any = Occurrence of a SAE, regardless of relationship to vaccination. | Up to Month 24 (Booster vaccination) | |
Primary | Number of Subjects With SAE(s) | A SAE was defined as any medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity in a subject. AE(s) considered as SAE(s) also included invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that did not result in hospitalization, as per the medical or scientific judgement of the physician. Any = Occurrence of a SAE, regardless of relationship to vaccination. | Up to Month 48 (Booster vaccination) | |
Primary | Number of Subjects With SAE(s) | A SAE was defined as any medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity in a subject. AE(s) considered as SAE(s) also included invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that did not result in hospitalization, as per the medical or scientific judgement of the physician. Any = Occurrence of a SAE, regardless of relationship to vaccination. | Within (31-Days) at Year 2 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00753649 -
Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants
|
Phase 4 | |
Completed |
NCT01214889 -
Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants.
|
Phase 3 | |
Completed |
NCT00534833 -
Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™
|
Phase 3 | |
Completed |
NCT00379977 -
Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of Age
|
Phase 3 | |
Completed |
NCT00153556 -
Study to Eliminate Hib Carriage in Rural Alaska Native Villages
|
Phase 4 | |
Completed |
NCT02853929 -
Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery
|
Phase 4 | |
Completed |
NCT02858440 -
A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia
|
Phase 3 | |
Completed |
NCT01983540 -
Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination
|
Phase 3 | |
Completed |
NCT01878435 -
Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western Kenya
|
N/A | |
Completed |
NCT00401531 -
Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infants
|
Phase 3 | |
Completed |
NCT00376779 -
Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age
|
Phase 2 | |
Completed |
NCT00831311 -
Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants
|
Phase 2 | |
Completed |
NCT01457547 -
Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Course
|
Phase 4 | |
Completed |
NCT00254917 -
Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines
|
Phase 4 | |
Completed |
NCT01453998 -
Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)
|
Phase 2 | |
Completed |
NCT01449812 -
Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine
|
Phase 3 | |
Completed |
NCT00808392 -
Safety and Immunogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b
|
Phase 3 | |
Completed |
NCT00307567 -
Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488
|
Phase 2 | |
Completed |
NCT00323050 -
Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Given to 14 Month Old Subjects
|
Phase 3 | |
Completed |
NCT00325156 -
Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants
|
Phase 4 |